Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00879905 Completed - Clinical trials for Advanced Solid Malignancies

A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors

Start date: May 2009
Phase: Phase 1
Study type: Interventional

This study will study the safety, tolerability and metabolism of a drug called HSP990 when given by mouth once a week or twice weekly to subjects with advanced solid tumors.

NCT ID: NCT00879684 Completed - Cancer Clinical Trials

Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors

Start date: January 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.

NCT ID: NCT00879554 Completed - Cancer Clinical Trials

A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors

CVX-045-101
Start date: February 2007
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.

NCT ID: NCT00878423 Completed - Clinical trials for Metastatic Solid Tumors

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

Start date: May 2008
Phase: Phase 1
Study type: Interventional

AT13387/0001 is a dose-finding study of an experimental anticancer agent. In accordance with the protocol increasing doses of AT13387 are given to patients with advanced cancer who do not have alternative treatment options. The preferred dose of AT13387 will be identified according to the side effects experienced at different dose levels.

NCT ID: NCT00877773 Terminated - Advanced Cancers Clinical Trials

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Start date: April 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if temsirolimus can help to control advanced cancer in patients who also have a PI3K mutation and/or PTEN loss. The safety of this drug will also be tested.

NCT ID: NCT00877136 Completed - Clinical trials for Hepatocellular Carcinoma

A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®

Start date: February 2009
Phase:
Study type: Observational

This is an interdisciplinary study that falls into the Humanitarian Use Device category. There are no hypotheses to be tested in this treatment protocol. The study has the following objectives: 1. Provide supervised access to treatment with TheraSphere® to eligible patients with primary cancer to the liver who are not surgical resection candidates. 2. Evaluate patient experience and toxicities associated with TheraSphere® treatment. 3. Measure tumor response rates

NCT ID: NCT00875433 Completed - Neoplasms Clinical Trials

Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours

Start date: March 2009
Phase: Phase 2
Study type: Interventional

A phase II trial to assess the impact of afatinib (BIBW 2992) on the heart (QTcF) and the effectiveness of afatinib (BIBW 2992) in treating certain cancers. Cancers studied will include glioblastoma and cancers which have spread to the brain (metastases).

NCT ID: NCT00875004 Terminated - Anemia Clinical Trials

Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors

PLATON
Start date: December 7, 2007
Phase: N/A
Study type: Interventional

RATIONALE: Epoetin beta may cause the body to make more red blood cells and may prevent or reduce side effects in patients undergoing chemotherapy for solid tumors. PURPOSE: This clinical trial is studying how well epoetin beta works in patients undergoing chemotherapy for solid tumors.

NCT ID: NCT00874731 Completed - Clinical trials for Metastatic or Locally Advanced Cancer

A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)

Start date: April 28, 2009
Phase: Phase 1
Study type: Interventional

To assess the potential for ridaforolimus to prolong the QTc interval (an effect on the electrical activity of the heart) in participants with advanced cancer. This study will be done in 2 parts. Part 1 (Pt 1) will evaluate the effect of a single 100 mg dose of ridaforolimus on QT interval in participants with advanced cancer. Fridericias's correction (QTcF) will be used. In Part 2 (Pt 2), participants will receive ridaforolimus at the current therapeutic dose (40 mg x 5 days).

NCT ID: NCT00871559 Completed - Clinical trials for Advanced Solid Malignancies

A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

Start date: June 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of REGN421 (SAR153192) in patients with advanced solid malignancies.